Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Refuse-to-Receive Challenges Become More Common – And More Successful

Executive Summary

Teva official calls for improved staff consistency as a new GDUFA headache emerges for FDA.


Related Content

Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
US FDA Wants Generic Sponsors To Know If Anything Missing Before Submitting ANDA
Industry Lauds, Worries About FDA Hiring Going Forward
FDA Ends ANDA 'Reviews' To Streamline Approval Process
Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says
FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
US FDA Outlines Internal ANDA Refuse-To-Receive Policy
Generic Application Quality Showing Signs Of Improvement
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts